Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best debt-free penny stocks to buy right now. On December 17, JPMorgan upgraded Recursion Pharmaceuticals (NASDAQ:RXRX) to an Overweight ...

Recursion Pharmaceuticals (RXRX) has been drawing attention after recent trading, with the stock closing at $4.67. Investors are weighing this price against the company’s clinical pipeline and ongoing ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Recursion Pharmaceuticals, Inc. is one of them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a ...

Sept 2 (Reuters) - Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results, in line with an FDA push to reduce animal testing in ...